News World
Trump’s pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.